Ionis Pharmaceuticals is a leader in RNA-based therapies. Its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The ...

RNA interference (RNAi) therapy offers groundbreaking potential to revolutionize disease treatment by targeting gene silencing. Opportunities lie in developing alternative treatments for conditions ...

Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.

University of Queensland research has revealed that double-stranded RNA-based biopesticides (dsRNA) sprayed on plant leaves ...

EQT Life Sciences is pleased to announce that the LSP Dementia Fund has co-led a USD 39 million Series A financing in Aerska, a biotechnology company leveraging brain shuttle technology to develop RNA ...

Messenger RNA (mRNA) technology is transforming medicine by providing our cells with genetic instructions to produce ...

The Irish start-up ecosystem had a busy start to the year, with many announcing significant funding rounds. Chief among the raises is quantum start-up Equal1, which announced a $60m round to help with ...

Brings total funds raised to $60 million since launch, months after its seed funding announcement in October 2025Appoints Arno de Wilde, Philip ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) gains attention across Nasdaq index fund holdings after upgrade and strong quarterly performance.

Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 ...